FDA relaxes drug approval standards: corporate influence accelerates market access over safety
Original framing: “FDA will drop two-study requirement for new drug approvals, aiming to speed access - Associated Press News” — AP News (via Google News)
The story omits historical context of the 1962 Kefauver-Harris Amendment that established the two-study requirement after thalidomide tragedies. It ignores alternative models like the EMA's risk-based approval system and excludes patient advocacy voices warning about accelerated approval pathways.
Low structural omission detected in mainstream coverage.
Produced by AP News for public consumption, this narrative serves pharmaceutical industry interests by framing deregulation as patient-centric progress. It obscures the FDA's role as a corporate gatekeeper, normalizing regulatory capture that benefits shareholders over long-term health outcomes.
Indigenous pharmacopeias developed over millennia use community-based, multi-generational testing for medicinal validation. Their exclusion from modern regulatory frameworks perpetuates a Eurocentric bias that values corporate R&D over traditional knowledge systems.
This regulatory shift exemplifies global healthcare's tension between market forces and public health ethics.